CD8A and rheumatoid arthritis: Notably, no significant differences of CD8+ T cell basal motility were found in untreated versus biologic disease‐modifying antirheumatic drug (bDMARD)–treated patients within cohorts of SpA (r‐axSpA and PsA) and RA (Supplementary Figure 3).